866-997-4948(US-Canada Toll Free)

Diabetic Macular Edema - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Oct 2013

Category :

Diabetes

No. of Pages : 120 Pages


Global Markets Directs, \'Diabetic Macular Edema Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema. Diabetic Macular Edema Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Diabetic Macular Edema.
  • A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Diabetic Macular Edema pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Macular Edema Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Diabetic Macular Edema 10
Diabetic Macular Edema Therapeutics under Development by Companies 12
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Diabetic Macular Edema Therapeutics - Products under Development by Companies 18
Companies Involved in Diabetic Macular Edema Therapeutics Development 20
F. Hoffmann-La Roche Ltd. 20
Allergan, Inc. 21
pSivida Corp. 22
GlaxoSmithKline plc 23
Quark Pharmaceuticals, Inc. 24
Santen Pharmaceutical Co., Ltd. 25
Lux Biosciences, Inc. 26
Novagali Pharma SA 27
Astellas Pharma Inc. 28
TheraKine Inc. 29
iCo Therapeutics Inc. 30
NicOx SA 31
Regeneron Pharmaceuticals, Inc. 32
ThromboGenics NV 33
Foamix Ltd. 34
Molecular Partners AG 35
Senju Pharmaceutical Co., Ltd. 36
Pfenex Inc. 37
Icon Bioscience, Inc. 38
Eleven Biotherapeutics 39
Ampio Pharmaceuticals, Inc. 40
Diabetic Macular Edema - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
ranibizumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
darapladib - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
iCo-007 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
dexamethasone acetate - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ocriplasmin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
aflibercept - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Drug For Diabetic Macular Edema - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
PF-655 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
fluocinolone acetonide - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
danazol - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
MP-0112 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
NCX-434 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
difluprednate - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
LX-213 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
ASP-440 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
NCX-422 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Ranibizumab Biosimilar - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Plasma Kallikrein Inhibitors Programme - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Plasma Kallikrein Inhibitors Programme - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
EBI-018 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Compound-10 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
OPK-20018 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
ranibizumab biosimilar - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Compound-37b - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Protein Therapeutic For Diabetic Macular Edema - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Therapy For Diabetic Macular Edema - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Diabetic Macular Edema Therapeutics - Drug Profile Updates 87
Diabetic Macular Edema Therapeutics - Discontinued Products 109
Diabetic Macular Edema Therapeutics - Dormant Products 110
Diabetic Macular Edema - Product Development Milestones 111
Featured News & Press Releases 111
Sep 30, 2013: pSivida Announces That U.K.’s NICE Recommends ILUVIEN for Chronic Diabetic Macular Edema in Pseudophakic Eyes; NHS Reimbursement Expected to Follow 111
Sep 27, 2013: New data for Novartis drug Lucentis reinforces transformational efficacy and well-established safety profile across four indications 111
Sep 17, 2013: Regeneron to Present Phase 3 Data for EYLEA Injection in Diabetic Macular Edema at Upcoming Retina Society Meeting 113
Aug 06, 2013: Regeneron and Bayer Report Positive One-Year Results from Two Phase 3 Trials of EYLEA Injection for the Treatment of Diabetic Macular Edema 113
Jul 24, 2013: pSivida Announces France\'s Transparency Commission Issues Positive Opinion for Reimbursement of ILUVIEN 115
Jun 18, 2013: iCo Therapeutics Announces Completion Of Trial Enrollment And Clinical Update For iDEAL Phase II Study For Treatment Of Diabetic Macular Edema 115
Jun 14, 2013: Alimera Sciences Announces Issuance Of Positive Appraisal Recommendation On Iluvien For Consultation In UK 116
Jun 03, 2013: Ampio Pharma Provides Clinical Update On Diabetic Macular Edema Drug, Optina 117
May 08, 2013: Novartis Reports New Data On Lucentis At Association For Research In Vision And Ophthalmology Annual Meeting 117
May 07, 2013: pSivida Announces Commercial Launch Of Iluvien In Germany 118

Appendix 119
Methodology 119
Coverage 119
Secondary Research 119
Primary Research 119
Expert Panel Validation 119
Contact Us 120
Disclaimer 120

List of Table


Number of Products Under Development for Diabetic Macular Edema, H2 2013 10
Products under Development for Diabetic Macular Edema - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Comparative Analysis by Late Stage Development, H2 2013 14
Comparative Analysis by Mid Clinical Stage Development, H2 2013 15
Comparative Analysis by Early Clinical Stage Development, H2 2013 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 17
Products under Development by Companies, H2 2013 18
Products under Development by Companies, H2 2013 (Contd..1) 19
F. Hoffmann-La Roche Ltd., H2 2013 20
Allergan, Inc., H2 2013 21
pSivida Corp., H2 2013 22
GlaxoSmithKline plc, H2 2013 23
Quark Pharmaceuticals, Inc., H2 2013 24
Santen Pharmaceutical Co., Ltd., H2 2013 25
Lux Biosciences, Inc., H2 2013 26
Novagali Pharma SA, H2 2013 27
Astellas Pharma Inc., H2 2013 28
TheraKine Inc., H2 2013 29
iCo Therapeutics Inc., H2 2013 30
NicOx SA, H2 2013 31
Regeneron Pharmaceuticals, Inc., H2 2013 32
ThromboGenics NV, H2 2013 33
Foamix Ltd., H2 2013 34
Molecular Partners AG, H2 2013 35
Senju Pharmaceutical Co., Ltd., H2 2013 36
Pfenex Inc., H2 2013 37
Icon Bioscience, Inc., H2 2013 38
Eleven Biotherapeutics, H2 2013 39
Ampio Pharmaceuticals, Inc., H2 2013 40
Assessment by Monotherapy Products, H2 2013 41
Assessment by Stage and Route of Administration, H2 2013 43
Assessment by Stage and Molecule Type, H2 2013 45
Diabetic Macular Edema Therapeutics - Drug Profile Updates 87
Diabetic Macular Edema Therapeutics - Discontinued Products 109
Diabetic Macular Edema Therapeutics - Dormant Products 110

List of Chart


Number of Products under Development for Diabetic Macular Edema, H2 2013 10
Products under Development for Diabetic Macular Edema - Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Late Stage Products, H2 2013 14
Mid Clinical Stage Products, H2 2013 15
Early Clinical Stage Products, H2 2013 16
Discovery and Pre-Clinical Stage Products, H2 2013 17
Assessment by Monotherapy Products, H2 2013 41
Assessment by Route of Administration, H2 2013 42
Assessment by Stage and Route of Administration, H2 2013 43
Assessment by Molecule Type, H2 2013 44
Assessment by Stage and Molecule Type, H2 2013 45

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *